Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Holding OPK?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 09, 2018
|% Change Since: 1.38%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment, driven by strategic asset sales, strong growth in key diagnostics areas, and significant financial improvements. Despite some revenue declines in specific segments, the company's overall financial health and strategic partnerships indicate a strong position moving forward.Company Guidance
During the OPKO Health Q3 2024 earnings call, key guidance metrics were provided for the upcoming quarter and beyond. The company anticipates total revenues for Q4 2024 to range between $155 million and $160 million. Revenue from services is expected to be between $95 million and $98 million, while product sales are projected to fall between $41 million and $44 million. Other revenue, inclusive of Pfizer gross profit share and BARDA revenue, is estimated to be between $13 million and $18 million. OPKO also forecasts fourth-quarter costs and expenses, excluding nonrecurring restructuring expenses, to be in the range of $200 million to $210 million. Research and development expenses are projected between $28 million and $34 million, partially offset by BARDA funding of $5 million to $8 million. Additionally, depreciation and amortization expenses are anticipated to be between $22 million and $23 million. The company aims for its diagnostics segment to achieve a breakeven run rate by year-end 2024 and positive cash flow and profitability in 2025, targeting a gross margin threshold above 27% and an overall increase in annual revenue by $8 million to $10 million in 2025.Sale of BioReference Health Assets
OPKO completed the sale of certain BioReference Health assets for $237.5 million. This transaction is expected to streamline operations and reduce costs, improving the path to profitability.
Growth in Oncology Testing Volume
BioReference Health reported a 6.8% increase in oncology testing volume in Q3 2024 compared to Q3 2023.
4Kscore Test Growth
The 4Kscore test, an FDA-approved prostate cancer test, delivered a 16% growth year-to-date over the same period in 2023.
Strong Financial Position
OPKO ended Q3 2024 with over $400 million in cash and cash equivalents, having repurchased and retired a total of 79 million shares year-to-date.
BARDA Contract Funding Increase
OPKO was awarded an additional $51 million under its BARDA contract for the development of COVID multi-specific antibodies and an influenza program.
Collaboration with Merck on Vaccine Development
OPKO's collaboration with Merck on an Epstein-Barr Virus vaccine is on track to enter the clinic soon, with potential milestone payments totaling $872.5 million.
Positive Financial Results
OPKO reported net income of $24.9 million in Q3 2024, a significant improvement from a net loss of $84.5 million in the same period in 2023.
---
OPK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
OPK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $1.45 | $1.52 | +4.83% |
| Aug 07, 2024 | $1.28 | $1.43 | +11.72% |
| May 07, 2024 | $1.30 | $1.25 | -3.85% |
| Feb 27, 2024 | $1.05 | $0.98 | -6.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Opko Health Inc (OPK) report earnings?
Opko Health Inc (OPK) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Opko Health Inc (OPK) earnings time?
Opko Health Inc (OPK) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPK EPS forecast?
OPK EPS forecast for the fiscal quarter 2024 (Q4) is -0.09.
---